

ASX MEDIA RELEASE

4 February 2022

## Clarity receives \$3.26 million R&D tax incentive refund

**Clarity Pharmaceuticals** (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a \$3,262,861 Research and Development (R&D) tax refund as part of the Australian Federal Government's R&D tax incentive, recognising the R&D undertaken by Clarity in the radiopharmaceutical field in the financial year ended 30 June 2021.

The R&D tax incentive is a program by the Australian Federal Government that encourages companies to engage and invest in R&D activities by providing a refundable tax offset of up to 43.5% of the eligible activities.

The tax refund is for all eligible R&D activities across Clarity's radiopharmaceutical programs. The receipt of \$3.26M in additional funding will further finance the development of Clarity's Targeted Copper Theranostics (TCT) platform of products for various cancer indications.

**Clarity's Executive Chairman, Dr Alan Taylor, commented,** "The R&D tax incentive provides Clarity with a valuable source of non-dilutive funding to assist us with investment in the development and validation of the TCT platform. Clarity continues to progress our portfolio of next-generation radiopharmaceutical products through clinical trials in the US and Australia in pursuit of our ultimate goal of improving treatment outcomes for children and adults with cancer."

*This announcement has been authorised for release by the Executive Chairman.*

**For more information, please contact:**

**Clarity Pharmaceuticals**

Dr Alan Taylor

**Executive Chairman**

[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

### About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)